EU Commission accuses Teva of breaking antitrust laws

According to the EU authority, the Israeli maker of generics has not only smeared a competitor but also forced them into lengthy legal proceedings to keep products off the market.

EU Commissioner for Competition Margrethe Vestager | Photo: Julien Warnand/EPA / EPA

What started off as a suspicion for EU Commissioner for Competition Margrethe Vestager has now turned into an accusation that Israeli generic medicines maker Teva has ”artificially” extended patent protection for multiple sclerosis treatment, Copaxone (glatiramer acetate), while smearing a competing drug.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs